series-c
Stage
About
EditForce develops proprietary RNA/DNA editing technologies based on pentatricopeptide repeat (PPR) proteins, applying these innovations to drug discovery and aiming to create new modalities for treating various diseases as well as applications in chemicals and agriculture.
Explore EditForce's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.